IntrinsicIntrinsic
← All summaries

AGENUS INC

AGEN
Financials & Chart →

Business Summary

Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease, with its primary business in immuno-oncology where it advances antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the population of patients who may benefit from immunotherapy. The company also maintains an equity investment in MiNK Therapeutics, Inc., with an approximate fair value of $24.3 million as of December 31, 2025, and a majority ownership of a vaccine adjuvant business through its subsidiary SaponiQx, Inc.

The immuno-oncology drug landscape is highly competitive, with numerous companies developing assets against a wide range of targets, and competitors range from small-cap to large-cap companies including programs in both pre-clinical and clinical stages of development. Named competitors include Bristol Myers Squibb, Merck & Co., Regeneron Pharmaceuticals, Roche/Genentech, AstraZeneca, Merck KGaA, GSK, Coherus BioSciences, Incyte, BeiGene, and Checkpoint Therapeutics, among others. For the specific indication of refractory colorectal cancer, competitors include AbbVie, Adagene, Exelixis, Jiangsu Alphamab Biopharmaceuticals, Merck & Co., Replimune, and Xilio Therapeutics.

Agenus generates revenue through a mix of research and development revenue from collaborations, pre-commercial product revenue from early access programs, service revenue, and non-cash royalty revenue related to the sale of future royalties. The company uses internal discovery, translational, clinical and regulatory capabilities together with selected collaborations to advance product candidates, and its primary customer segments are collaboration partners such as Bristol Myers Squibb, Incyte, Merck & Co., and GSK, as well as patients accessing therapies through regulatory-authorized early access pathways.

The company's lead clinical program is botensilimab (BOT or AGEN1181), a multifunctional anti-CTLA-4 antibody designed to activate both innate and adaptive anti-tumor immune responses, alone and in combination with balstilimab (BAL), a fully human monoclonal immunoglobulin G4 anti-PD-1 antibody. BOT and BAL are investigational therapies and have not been approved by the FDA or the European Medicines Agency for commercial sale, however they are accessible through government reimbursement programs in France as well as through out of pocket pay in select European and South American countries. BOT, alone and in combination with BAL, has been evaluated in approximately 1,200 patients across more than 60 centers worldwide and across nine tumor types, including colorectal cancer, sarcoma, non-small cell lung cancer, hepatocellular cancer, pancreatic cancer, melanoma, ovarian cancer and triple negative breast cancer. In April 2023, BOT in combination with BAL received Fast Track designation from the FDA for the treatment of patients with non-microsatellite instability-high and/or deficient mismatch repair metastatic colorectal cancer without active liver involvement. The company also maintains select clinical-stage immuno-oncology assets including AGEN2373 (CD137 agonist antibody), AGEN1423 (CD73/TGFβ TRAP), AGEN1571 (ILT2), and AGEN1777 (TIGIT bispecific), which were temporarily postponed as part of the December 2024 strategic realignment.

In June 2025, the company announced a strategic collaboration with Zydus Lifesciences Ltd., including the sale of its Emeryville and Berkeley biologics manufacturing facilities, with a total consideration of $91.0 million , which closed in January 2026. In May 2024, the company entered into a Purchase and Sale Agreement with Ligand Pharmaceuticals Incorporated covering specified economic interests in selected partnered programs and in BOT and BAL, under which Ligand acquired 31.875% of the development, regulatory and commercial milestones then payable to the company under agreements with BMS, UroGen, Gilead, Merck and Incyte, 18.75% of the royalties under those agreements, and a 2.625% synthetic royalty on worldwide net sales of BOT and BAL. In July 2024, BMS notified the company that it was voluntarily terminating the license agreement for AGEN1777 effective January 26, 2025, and rights were returned to the company. In February 2025, the company received formal notice from Incyte terminating the collaboration effective February 2026, and all rights to LAG-3 and TIM-3 were returned to the company. In July 2025, the company's ownership percentage of MiNK dropped below 50%, resulting in a loss of control and deconsolidation in the quarter ended September 30, 2025, and as of December 31, 2025, the company owned approximately 46% of MiNK. In January 2026, France expanded the AAC protocol for botensilimab plus balstilimab to include certain ovarian cancers and soft-tissue sarcomas. In January 2026, the company closed its strategic collaboration with Zydus Lifesciences Ltd., including the sale of its Emeryville and Berkeley biologics manufacturing facilities, with a total consideration of $91.0 million .

Total revenues for the year ended December 31, 2025 were $114.196 million , compared to $103.463 million for the year ended December 31, 2024. Net loss attributable to Agenus Inc. common stockholders was $0.101 million for 2025, compared to $227.427 million for 2024. The company recognized pre-commercial product revenue of approximately $4.2 million during 2025, representing sales of BOT+BAL provided to patients through regulatory-authorized early access pathways. Non-cash royalty revenue related to the GSK agreement increased to approximately $108.6 million for 2025 from $101.0 million for 2024. Research and development expense decreased 49% to $79.3 million for 2025 from $155.5 million for 2024. The company recognized a gain from deconsolidation of MiNK Therapeutics, Inc. of $100.9 million for 2025.

Business Outlook

The company intends in 2026 to seek Accelerated Approval in the United States and Conditional Approval in the European Union for BOT plus BAL in refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. The company, together with the Canadian Cancer Trials Group, is conducting BATTMAN/CO.33, a global Phase 3 trial of botensilimab plus balstilimab versus best supportive care in refractory MSS/mismatch repair proficient colorectal cancer, which is expected to enroll approximately 830 patients across more than 100 sites in Canada, France, Australia and New Zealand and is intended to support potential regulatory filings in the United States and Europe.

The company is evaluating potential future registration-enabling trial designs in neoadjuvant, first-line and later-line colorectal cancer, informed by data from studies including the NEST study which showed a pathological complete response rate improved to 47% in MSS tumors when the median time to surgery was extended, and the UNICORN Phase 2 study which showed patients with dMMR/MSI-H tumors achieved a 93% pCR and 100% pMR, while patients with pMMR/MSS colorectal cancer had a 29% pCR and 36% pMR rate. Whether and when any additional registration-enabling trials will be initiated will depend on capital availability and strategic transactions, including partnerships, licensing arrangements and joint ventures.

Research and development expense decreased 49% to $79.3 million for the year ended December 31, 2025 from $155.5 million for the year ended December 31, 2024, primarily due to a $51.9 million decrease in third-party services and other expenses, a $14.3 million decrease in personnel related expenses, a $2.0 million decrease in other research and development expenses, and a $7.9 million decrease in expenses attributable to the activities of subsidiaries. General and administrative expense decreased 24% to $54.4 million for 2025 from $71.9 million for 2024, primarily due to a $9.1 million decrease in personnel related expenses, a $3.4 million decrease other general and administrative expenses and a $5.1 million decrease in expenses attributable to the activities of subsidiaries.

In January 2026, the company divested its assets that comprised its in-house planned manufacturing division, including the sale of its owned facility in Berkeley, California as well as its leasehold interest in its facility in Emeryville, California, and entered into a contract manufacturing agreement with Zydus for certain of its manufacturing needs. As of February 28, 2026, the company had 81 employees, of whom 19 held Ph.D. degrees and 5 held M.D. degrees.

The company's research and development expenses for the years ended December 31, 2025, 2024, and 2023, were $79.3 million , $155.5 million , and $234.6 million , respectively. The company maintains an effective registration statement covering up to $300.0 million of common stock, preferred stock, warrants, debt securities and units, which includes prospectuses covering the offer, issuance and sale of up to 20.6 million shares of common stock from time to time in at-the-market offerings pursuant to an At Market Issuance Sales Agreement with B. Riley Securities, Inc. The company sold approximately 9.7 million and 0.2 million shares of its common stock pursuant to the Sales Agreement during the year ended December 31, 2025 and the period of January 1, 2026 through March 12, 2026, respectively, and received aggregate net proceeds totaling $36.9 million . As of March 12, 2026, approximately 8.2 million shares remained available for sale under the Sales Agreement.

The company has historically incurred net losses and anticipates that it will continue to incur net losses in the future, with net losses for the years ended December 31, 2025, 2024, and 2023, of $3.1 million , $232.3 million and $257.4 million , respectively. As of December 31, 2025, the company had $3.0 million of cash and cash equivalents. Based on its current plans and projections, the company believes that its cash resources as of December 31, 2025, plus funding received in the first quarter of 2026 and anticipated funding will be sufficient to satisfy its critical liquidity requirements into 2027. However, the company will in any event require additional capital in order to complete clinical development of its current programs.

The company's ability to use net operating losses and research and development credits to offset future taxable income may be subject to certain limitations. As of December 31, 2025, the company had U.S. federal and state net operating loss carryforwards of $992.4 million and $532.5 million , respectively, which may be available to offset future taxable income. The federal NOLs include $445.9 million which expire at various dates through 2044 and $546.5 million which carryforward indefinitely. As of December 31, 2025, the company also had U.S. federal and state research and development tax credit carryforwards of $3.8 million and $1.2 million , respectively, which may be available to offset future tax liabilities and begin to expire in 2026.

Risk Factors

The company's business is highly dependent on the success of botensilimab and related combination therapy programs, which still require significant additional clinical development, and there is no guarantee that these product candidates will be approved or successfully commercialized. The company has incurred net losses in every year since its inception, with net losses for the years ended December 31, 2025, 2024, and 2023 of $3.1 million , $232.3 million and $257.4 million , respectively, and as of December 31, 2025 had an accumulated deficit of $2.18 billion . As of December 31, 2025, the company had only $3.0 million of cash and cash equivalents, and its independent registered public accounting firm has included an explanatory paragraph relating to its ability to continue as a going concern in its report on the audited financial statements. The company faces intense competition from major pharmaceutical companies and specialized biotechnology companies with substantially greater financial, technical and other resources, and many competitors have products on the market or in development for the treatment of cancer. The company's ability to use its net operating loss carryforwards of $992.4 million (federal) and $532.5 million (state) may be subject to limitations under Sections 382 and 383 of the Code due to ownership changes, and the company may not be able to utilize a material portion of these NOLs.

Management Priorities

Management's message emphasizes a strategic focus on capital execution for programs with the clearest path to meaningful clinical and commercial value, led by BOT/BAL in colorectal cancer and selected other tumor types, following a strategic realignment announced in December 2024 that prioritized the botensilimab/balstilimab program and temporarily paused certain non-core preclinical and clinical activities while evaluating partnering and targeted funding opportunities. The company intends in 2026 to seek Accelerated Approval in the United States and Conditional Approval in the European Union for BOT plus BAL in refractory microsatellite-stable metastatic colorectal cancer without active liver metastases. Key strategic priorities include advancing late-stage development of BOT/BAL, supporting responsible paid patient access programs as well as clinical trials, and maintaining manufacturing flexibility through strategic collaborations with an emphasis on the Zydus collaboration.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business — Our Business
  2. [2] Item 1, Business — Lead Program: Botensilimab and Balstilimab
  3. [3] Item 1, Business — Lead Program: Botensilimab and Balstilimab
  4. [4] Item 1, Business — Recent Developments
  5. [5] Item 1, Business — Ligand
  6. [6] Item 1, Business — Ligand
  7. [7] Item 1, Business — Ligand
  8. [8] Item 1, Business — Equity Investment in MiNK and Subsidiary SaponiQx
  9. [9] Item 1, Business — Recent Developments
  10. [10] Item 8, Consolidated Statements of Operations
  11. [11] Item 8, Consolidated Statements of Operations
  12. [12] Item 8, Consolidated Statements of Operations
  13. [13] Item 8, Consolidated Statements of Operations
  14. [14] Item 7, MD&A — Historical Results of Operations
  15. [15] Item 7, MD&A — Historical Results of Operations
  16. [16] Item 7, MD&A — Historical Results of Operations
  17. [17] Item 7, MD&A — Historical Results of Operations
  18. [18] Item 7, MD&A — Historical Results of Operations
  19. [19] Item 8, Consolidated Statements of Operations
  20. [20] Item 1, Business — Refractory MSS Metastatic Colorectal Cancer
  21. [21] Item 1, Business — Refractory MSS Metastatic Colorectal Cancer
  22. [22] Item 1, Business — Additional Colorectal Cancer Studies
  23. [23] Item 1, Business — Additional Colorectal Cancer Studies
  24. [24] Item 1, Business — Additional Colorectal Cancer Studies
  25. [25] Item 1, Business — Additional Colorectal Cancer Studies
  26. [26] Item 1, Business — Additional Colorectal Cancer Studies
  27. [27] Item 7, MD&A — Historical Results of Operations
  28. [28] Item 7, MD&A — Historical Results of Operations
  29. [29] Item 7, MD&A — Historical Results of Operations
  30. [30] Item 7, MD&A — Historical Results of Operations
  31. [31] Item 7, MD&A — Historical Results of Operations
  32. [32] Item 7, MD&A — Historical Results of Operations
  33. [33] Item 7, MD&A — Historical Results of Operations
  34. [34] Item 7, MD&A — Historical Results of Operations
  35. [35] Item 7, MD&A — Historical Results of Operations
  36. [36] Item 7, MD&A — Historical Results of Operations
  37. [37] Item 7, MD&A — Historical Results of Operations
  38. [38] Item 1, Business — Human Capital Resources and Employees
  39. [39] Item 1, Business — Human Capital Resources and Employees
  40. [40] Item 1, Business — Human Capital Resources and Employees
  41. [41] Item 7, MD&A — Overview
  42. [42] Item 7, MD&A — Overview
  43. [43] Item 7, MD&A — Overview
  44. [44] Item 7, MD&A — Liquidity and Capital Resources
  45. [45] Item 7, MD&A — Liquidity and Capital Resources
  46. [46] Item 7, MD&A — Liquidity and Capital Resources
  47. [47] Item 7, MD&A — Liquidity and Capital Resources
  48. [48] Item 7, MD&A — Liquidity and Capital Resources
  49. [49] Item 7, MD&A — Liquidity and Capital Resources
  50. [50] Item 1A, Risk Factors — Summary of Risk Factors
  51. [51] Item 1A, Risk Factors — Summary of Risk Factors
  52. [52] Item 1A, Risk Factors — Summary of Risk Factors
  53. [53] Item 1A, Risk Factors — Risks Related to Our Financial Position
  54. [54] Item 1A, Risk Factors — Risks Related to Government Regulations
  55. [55] Item 1A, Risk Factors — Risks Related to Government Regulations
  56. [56] Item 1A, Risk Factors — Risks Related to Government Regulations
  57. [57] Item 1A, Risk Factors — Risks Related to Government Regulations
  58. [58] Item 1A, Risk Factors — Risks Related to Government Regulations
  59. [59] Item 1A, Risk Factors — Risks Related to Government Regulations
  60. [60] Item 1A, Risk Factors — Summary of Risk Factors
  61. [61] Item 1A, Risk Factors — Summary of Risk Factors
  62. [62] Item 1A, Risk Factors — Summary of Risk Factors
  63. [63] Item 8, Consolidated Balance Sheets
  64. [64] Item 1A, Risk Factors — Risks Related to Our Financial Position
  65. [65] Item 1A, Risk Factors — Risks Related to Government Regulations
  66. [66] Item 1A, Risk Factors — Risks Related to Government Regulations
  67. [67] Item 8, Consolidated Statements of Operations
  68. [68] Item 8, Consolidated Statements of Operations
  69. [69] Item 8, Consolidated Statements of Operations
  70. [70] Item 8, Consolidated Statements of Operations
  71. [71] Item 8, Consolidated Statements of Operations
  72. [72] Item 8, Consolidated Statements of Operations
  73. [73] Item 8, Consolidated Statements of Operations
  74. [74] Item 8, Consolidated Statements of Operations
  75. [75] Item 8, Consolidated Statements of Operations
  76. [76] Item 8, Consolidated Statements of Operations
  77. [77] Item 8, Consolidated Statements of Operations
  78. [78] Item 8, Consolidated Statements of Operations
  79. [79] Item 8, Consolidated Balance Sheets
  80. [80] Item 8, Consolidated Balance Sheets
  81. [81] Item 8, Consolidated Balance Sheets
  82. [82] Item 7, MD&A — Historical Results of Operations
  83. [83] Item 7, MD&A — Historical Results of Operations
  84. [84] Item 7, MD&A — Historical Results of Operations
  85. [85] Item 7, MD&A — Historical Results of Operations
  86. [86] Item 7, MD&A — Historical Results of Operations
  87. [87] Item 7, MD&A — Historical Results of Operations

Analysis on 6/21/2026